Scientific article
Open access

Syndrome de Widal : manifestations cliniques, physiopathologie et avancées thérapeutiques

Other titleWidal's triad : clinical manifestations, pathophysiology and therapeutic advances
Published inRevue médicale suisse, vol. 16, no. 689, p. 694-697
Publication date2020-04-08

NSAID-Exacerbated respiratory disease (also known as Samter's or Widal's triad, aspirin-exacerbated respiratory disease) is characte- rized by asthma, nasal polyposis and hypersensitivity to NSAIDs. The pathogenesis of this chronic inflammation arises from an imbalance in arachidonic acid metabolism, leading to an increase in pro- inflammatory cysteinyl-leukotrienes. The treatment is based on drug management of asthma and polyps and, in advanced situations, surgical management of polyposis. Monoclonal antibodies have shown promising results in the further medical treatment of this entity.

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / immunology
  • Aspirin / adverse effects
  • Aspirin / immunology
  • Asthma / chemically induced
  • Drug Hypersensitivity
  • Humans
  • Nasal Polyps / chemically induced
  • Sinusitis / chemically induced
Citation (ISO format)
VANDENBERGHE-DÜRR, Sophie, LANDIS, Basile Nicolas, JANDUS, Peter. Syndrome de Widal : manifestations cliniques, physiopathologie et avancées thérapeutiques. In: Revue médicale suisse, 2020, vol. 16, n° 689, p. 694–697.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation03/15/2022 9:34:00 PM
First validation03/15/2022 9:34:00 PM
Update time04/06/2023 3:50:08 PM
Status update03/16/2023 2:54:42 AM
Last indexation01/17/2024 4:36:00 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack